Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
50 participants
INTERVENTIONAL
2017-01-18
2017-03-02
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Repeat Insult Patch Test APPENDIX I to HRL Standard Protocol #100
NCT03450070
Human Repeated Insult Patch Test
NCT03474874
To Assess Skin Safety of Test Product(s) by Patch Test on Adult Healthy Human Subjects
NCT07109453
Human Skin Safety Testing of a Mitopure Topical Product Using a Human Repeat Insult Patch Test (HRIPT) in Healthy Volunteers
NCT05079607
Study Will Assess Skin Irritation and Sensitization for HP-1050 Patch
NCT04624867
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
SCREENING
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Test product
CB-0002B
CB-0002B (choline geranate) is a viscous transparent colorless to light yellow liquid
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
CB-0002B
CB-0002B (choline geranate) is a viscous transparent colorless to light yellow liquid
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Individuals free of any dermatological or systemic disorder which would interfere with the results, at the discretion of the Investigator.
* Individuals free of any acute or chronic disease that might interfere with or increase the risk of study participation.
* Individuals who will complete a preliminary medical history form mandated by AMA Laboratories, Inc. and are in general good health.
* Individuals, who will read, understand and sign an informed consent document relating to the specific type of study they are subscribing. Consent forms are kept on file and are available for examination on the premises of AMA Laboratories, Inc. only.
* Individuals able to cooperate with the Investigator and research staff, willing to have test materials applied according to the protocol, and complete the full course of the study.
Exclusion Criteria
* Individuals who are currently under a doctor's care.
* Individuals who are currently taking any medication (topical or systemic) that may mask or interfere with the test results.
* Subjects with a history of any acute or chronic disease that might interfere with or increase the risk associated with study participation.
* Individuals diagnosed with chronic skin allergies.
* Female volunteers who indicate that they are pregnant or lactating.
21 Years
67 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AMA Laboratories Inc.
UNKNOWN
CAGE Bio Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Director
Role: STUDY_DIRECTOR
AMA Laboratories Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
AMA Laboratories Inc.
New City, New York, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MS17.RIPT.P1200O.50.CBIO
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.